Journal
PHARMACOGENETICS AND GENOMICS
Volume 19, Issue 8, Pages 613-625Publisher
LIPPINCOTT WILLIAMS & WILKINS
DOI: 10.1097/FPC.0b013e32832f3010
Keywords
DNA repair; esophageal cancer; genetic polymorphisms
Funding
- NCI NIH HHS [K23 CA093401-03, K23 CA093401-01A2, R01 CA074386-11, K23 CA093401-04, K23 CA093401, R01 CA074386, K23 CA093401-05, K23 CA093401-02] Funding Source: Medline
Ask authors/readers for more resources
Objectives Genetic variations or polymorphisms within genes of the nucleotide excision repair (NER) pathway alter DNA repair capacity. Reduced DNA repair (NER) capacity may result in tumors that are more susceptible to cisplatin chemotherapy, which functions by causing DNA damage. We investigated the potential predictive significance of functional NER single nucleotide polymorphisms in esophageal cancer patients treated with (n=262) or without (n=108) cisplatin. Methods Four NER polymorphisms XPD Asp312Asn; XPD Lys751Gln, ERCC1 8092C/A, and ERCC1 codon 118C/T were each assessed in polymorphism-cisplatin treatment interactions for overall survival (OS), with progression-free survival (PFS) as a secondary endpoint. Results No associations with ERCC1 118 were found. Polymorphism-cisplatin interactions were highly significant in both OS (P=0.002, P=0.0001, and P<0.0001) and PFS (P=0.006, P=0.008, and P=0.0007) for XPD 312, XPD 751, and ERCC1 8092, respectively. In cisplatin-treated patients, variant alleles of XPD 312, XPD 751, and ERCC1 8092 were each associated with significantly improved OS (and PFS): adjusted hazard ratios of homozygous variants versus wild-type ranged from 0.22 [95% confidence interval (Cl): 0.1-0.5] to 0.31 (95% Cl: 0.1-0.7). In contrast, in patients who did not receive cisplatin, variant alleles of XPD 751 and ERCC1 8092 had significantly worse survival, with adjusted hazard ratios of homozygous variants ranging from 2.47 (95% Cl: 1.1-5.5) to 3.73 (95% Cl: 1.6-8.7). Haplotype analyses affirmed these results. Conclusion DNA repair polymorphisms are associated with OS and PFS, and if validated may predict for benefit from cisplatin therapy in patients with esophageal cancer. Pharmacogenetics and Genomics 19:613-625 (C) 2009 Wolters Kluwer Health | Lippincott Williams & Wilkins.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available